新冠病毒奥密克戎变异株的加强针策略是否足够？
Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?
作者信息
Chavda Vivek P, Apostolopoulos Vasso
机构信息
Department of Pharmaceutics and Pharmaceutical Technology, L M College of Pharmacy, Ahmedabad 380008, Gujrat, India.
Institute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia.
出版信息
Vaccines (Basel). 2022 Feb 26;10(3):367. doi: 10.3390/vaccines10030367.
The Omicron variant of SARS-CoV-2 is emerging in communities where people were previously infected with SARS-CoV-2 and are now being vaccinated, or where many people have received two or three coronavirus vaccination doses. More than 130 countries around the globe have implemented booster dose programs for tackling omicron endemics. Despite early findings shows that booster doses may improve omicron protection, more research is needed to establish vaccination efficacy. This short communication tries to critically discuss the research work findings around booster dose strategy for omicron endemics.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的奥密克戎变异株正在一些社区出现，这些社区的人们此前曾感染过SARS-CoV-2，现在正在接种疫苗，或者有许多人已经接种了两剂或三剂新冠病毒疫苗。全球130多个国家已实施加强针计划以应对奥密克戎流行情况。尽管早期研究结果表明加强针可能会增强对奥密克戎的防护力，但仍需要更多研究来确定疫苗的有效性。本简短通讯试图批判性地讨论围绕奥密克戎流行情况的加强针策略的研究工作结果。
Zotero 插件